Supply, distribution agreement between Watson, Sanofi-Aventis to expire

CORONA, Calif. A supply and distribution agreement between Watson Pharmaceuticals and Sanofi-Aventis will expire at the end of the year, the Swiss Chambers of Commerce Court of Arbitration has ruled.

The agreement will expire Dec. 31, meaning that Watson can continue to market and cell the anemia drug Ferrlecit (sodium ferric gluconate complex in sucrose) until then.

“We are very pleased with the panel’s decision, which affirms our right to market Ferrlecit and allows us to continue our commitment to the nephrology community,” Watson president and CEO Paul Bisaro stated. “We have plans to continue our direct marketing efforts in nephrology, as well as extending the nephrology team’s selling and marketing efforts to new products and areas where this seasoned sales force can provide additional value.”